On individual preferences and aggregation in economic evaluation in healthcare
- PMID: 11383750
- DOI: 10.2165/00019053-200119040-00001
On individual preferences and aggregation in economic evaluation in healthcare
Abstract
For practical reasons, in order to carry out economic evaluations of collective decisions, total costs will generally be compared with total benefits; hence, individuals' willingness to pay (WTP) or quality-adjusted life-years (QALYs) have to be estimated at an aggregate level. So far, aggregation has usually been done by taking the individuals' mean WTP or the unweighted number of QALYs. Since the aggregation process is closely related to the way that income, health and/or utility of different individuals are compared and weighted, it also has significant equity implications. Thus. the explicit (or, more often, implicit) assumptions behind the aggregation process will largely affect how health and welfare are distributed is society. The aggregation problem in economic evaluation is certainly not trivial, but is seldom addressed in current practice. This paper shows the underlying assumptions of aggregate cost-benefit analysis (CBA) and cost-effectiveness analysis/cost-utility analysis (CEA/CUA), and it emphasises the particularly strong assumptions which have to be made when QALYs are interpreted as utilities in the welfare economics sense. Naturally, the appropriate method to choose depends on what is to be maximised: welfare or health. If decisions of resource allocation are to be based on economic welfare theory, then CBA should be preferred. However, if QALYs are interpreted as measures of health, rather than as utilities, then CEA/CUA would be appropriate.
Similar articles
-
Measures of efficiency in healthcare: QALMs about QALYs?Z Evid Fortbild Qual Gesundhwes. 2010;104(3):214-26. doi: 10.1016/j.zefq.2010.03.012. Z Evid Fortbild Qual Gesundhwes. 2010. PMID: 20608250
-
Willingness to pay for a QALY: theoretical and methodological issues.Pharmacoeconomics. 2005;23(5):423-32. doi: 10.2165/00019053-200523050-00002. Pharmacoeconomics. 2005. PMID: 15896094 Review.
-
Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis?J Health Econ. 2002 Sep;21(5):827-43. doi: 10.1016/s0167-6296(02)00011-5. J Health Econ. 2002. PMID: 12349884
-
A utility-theoretic model for QALYs and willingness to pay.Health Econ. 2003 Jan;12(1):17-31. doi: 10.1002/hec.697. Health Econ. 2003. PMID: 12483758
-
Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses.Value Health. 2002 Jul-Aug;5(4):338-46. doi: 10.1046/j.1524-4733.2002.54134.x. Value Health. 2002. PMID: 12102696 Review.
Cited by
-
Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.BMJ Open. 2015 Oct 5;5(10):e008123. doi: 10.1136/bmjopen-2015-008123. BMJ Open. 2015. PMID: 26438135 Free PMC article.
-
The impact of economic evaluation on quality management in spine surgery.Eur Spine J. 2009 Aug;18 Suppl 3(Suppl 3):338-47. doi: 10.1007/s00586-009-0939-3. Epub 2009 Apr 1. Eur Spine J. 2009. PMID: 19337760 Free PMC article. Review.
-
Clinical and economic impact of epoetins in cancer care.Pharmacoeconomics. 2004;22(16):1029-45. doi: 10.2165/00019053-200422160-00001. Pharmacoeconomics. 2004. PMID: 15524492 Review.
-
Political economics in health and implications for neurosurgery diseases.Front Public Health. 2025 Jan 28;12:1444249. doi: 10.3389/fpubh.2024.1444249. eCollection 2024. Front Public Health. 2025. PMID: 39935745 Free PMC article. Review.
-
A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?Pharmacoeconomics. 2007;25(2):107-27. doi: 10.2165/00019053-200725020-00004. Pharmacoeconomics. 2007. PMID: 17249854 Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical